Hyperkalemia Drug May Help CKD Patients Stay on Spironolactone for Resistant Hypertension
It is challenging for CKD patients to stay on spironolactone therapy because it can increase the risk of hyperkalemia, according to researchers.
Diagnosis & Disease Information
Nearly Half of Type 2 Diabetics Have Undiagnosed CKD
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
Metabolic Acidosis Increases Risk of Adverse Renal Outcomes, Death
In a large study of patients with chronic kidney disease, metabolic acidosis independently increased the risk of progressing to end-stage renal disease and death.
Upper Arm AVFs May Be the Better Option for Patients Initiating HD
In a study, upper arm arteriovenous fistulas were associated with better hemodialysis access survival.
Clinical Parameters Interrelate Prior to Dialysis
The interdependence of trajectories in patient parameters, such as albumin and white blood cell count, may suggest certain disease processes.
CRBSI Clinical Presentation Varies by Causative Pathogen
Patients with Staphylococcus aureus catheter-related bloodstream infections are the most likely to present with fever, rigor, or both, a study found.
Staying on Sucroferric Oxyhydroxide May Cut Hospitalization Rate
Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.
Potassium Binders Linked With Fewer Emergency Department Visits
Prescription patterns suggest patiromer is used more often for chronic treatment of hyperkalemia and polystyrene sulfonate for episodic treatment.
Low Hypokalemia Rates Observed With Short-Term Patiromer Use
In a study of hemodialysis patients, only 0.6%, 0.5%, and 0.9% hypokalemia events occurred at 1, 2, and 3 months after initiating patiromer treatment.
Dementia Predicts CKD Progression, Death in Type 2 Diabetes
In type 2 diabetes patients, a dementia diagnosis preceded vascular events such as kidney disease progression by a mean 2998 days or roughly 8 years.
- Loading...
Loading...
Next post in NKF 2019 Spring Conference
Loading... 
Loading...